Barclays Maintains Equal-Weight on Summit Therapeutics, Lowers Price Target to $18
Benzinga Newsdesk 17 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Barclays analyst Etzer Darout maintains Summit Therapeutics (NASDAQ:SMMT) with a Equal-Weight and lowers the price target from $20 to $18.
Barclays analyst Etzer Darout maintains Summit Therapeutics (NASDAQ:SMMT) with a Equal-Weight and lowers the price target from $20 to $18.
